Hospital

Data analysis can help hospitals address waste of controlled substances that fuels diversion and increased costs.

Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).

Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.

This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, enabling a more comprehensive understanding of ocrelizumab’s safety.

The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Women who received epidural analgesia during labor were less likely to experience severe maternal morbidity complications, such as heart attack or heart failure and sepsis.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

The study compares the safety and efficacy of mRNA-1345 compared to placebo.

Pediatric patients with rheumatic disease, such as systemic lupus erythematosus, mixed connective tissue disease, juvenile dermatomyositis, and systemic vasculitis are at an increased risk of serious infection.

Topline results of QWINT-2 and QWINT-4 met the primary end point of change in hemoglobin A1c compared to degludec and glargine, respectively, for those with type 2 diabetes.

A review of asthma guidelines, pharmacotherapy, and the role of the pharmacist.

Tools provide a safer testing option without using the viral proteins that cause infection.

Lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) is a CD19-directed CAR T-cell therapy that is delivered as a one-time infusion.

Individuals from a lower socioeconomic group showed more benefits from low-dose CT screening relating to lung cancer survival.

Small steps can accumulate and have a big impact on patients’ lives

Penelope Murphy discusses the role that preceptors play in mentoring students and new pharmacists to help bridge the gap between classroom learning and real-world practice.

An inclusive apprenticeship program aligns with evolving roles, fosters growth, and positively affects patient care.

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

UC Davis Health researchers uncover substantial treatment disparities and inequal access to autologous hematopoietic cell transplantation therapy among multiple myeloma patients.

The findings demonstrated that daytime heat waves were associated with approximately 19% higher odds of asthma-related hospitalizations in children.

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.

Continued disparities of gender representation in cardiovascular research reveal oversights that impact adequate diagnosis and treatment of cardiovascular disease in women.

The role of semaglutide as a glucagon-like peptide-1 (GLP-1) receptor antagonist could offer further treatment options to improve patient outcomes.

A transformational leader can make the difference between an efficient, profitable organization and one that is mired in mediocrity.

Jodi Taraba, PharmD, MS, BCOP, offers insights on the benefits of involving oncology pharmacists in clinical trial research to advance treatment and care for patients with cancer.

Clinical trials are using AI to handle large and complex volumes of data to develop oncology, cardiovascular, and neurologic compounds and to integrate molecular and imaging data.

The pharmaceutical landscape faces challenges with drug serialization, including data discrepancies and potential shortages, but technology emerges as a beacon of hope for the industry.

The results showed that during a 1-month hospital stay, 13% of individuals who experienced RSV-associated acute respiratory failure died.

Test your knowledge of pharmacy with a quiz in collaboration with PTCE.

The results showed that individuals treated with milvexian had a prolonged aPTT in a dose-dependent manner with limited effects of PT.